Paresia del VI par craneal tras anestesia epidural
MRI FLAIR sequence. Homogeneous dural enhancement.
hygromas were present. As the headache and diplopia persisted despite hydration and analgesia, we consulted with the anaesthesiology division and decided to treat with a 20 cc autologous blood patch at 72 hours after onset of VI CNP. The patient's headache and diplopia both improved gradually in the 24 hours following the procedure. The patient was discharged 72 hours after treatment, at which time the diplopia had abated and she was able to stand without experiencing further headaches.
Although most published cases report complete and spontaneous resolution of VI CNP after LP within several weeks or even months after onset of the deficit, there are also other cases that do not progress well and require more aggressive treatment, including surgical treatment. 2, 3 Diplopia and headache are debilitating symptoms that limit patients' daily life activities and require use of the most effective treatment possible. The literature states that autologous blood patches are only effective for cases of post-LP headaches and diplopia in which treatment is initiated in the first 24 hours after VI CNP appears. [4] [5] [6] The interesting feature of this case is that treatment delivered excellent results even though the epidural blood patch was administered 72 hours after palsy onset.
In conclusion, we would like to suggest considering treatment with an epidural blood patch even when more than 24 hours have passed since the onset of CNP. This treatment may significantly accelerate the patient's recovery.
Painful polyneuropathy secondary to prolonged treatment with linezolid: Presentation of a case ଝ Polineuropatía dolorosa secundaria a tratamiento prolongado con linezolid: a propósito de un caso
Dear Editor:
Polyneuropathy is a common disease that requires an exhaustive aetiological study. Even so, the cause goes undiscovered on some occasions. Toxic neuropathies represent a small percentage of this group's diseases; some cases may be reversible, which makes identifying them all the more important. 1 At present, the appearance of new drugs such as linezolid means that we have to be espe- cially alert in order to detect potential neurotoxic side effects that had not been described before those drugs were marketed.
Our patient was a 24-year-old female smoker (20 cigarettes per day) with no other history of drug use. She was being treated with paroxetine for depressive disorder and used a vaginal ring; there was no other relevant medical or surgical history. She was referred to the hospital by her primary care doctor, who had observed positive Mantoux and bacilloscopy in a contact tracing study; her partner had recently been diagnosed with pleuropulmonary TB. Upon admission, the patient was completely asymptomatic and reported no fever, wasting syndrome, or respiratory problems. We began treatment with isoniazid, rifampicin, and pyrazinamide. After checking for good tolerance to the treatment (the patient only showed a slight increase in uric acid caused by the pyrazinamide) and a negative bacilloscopy, the patient was discharged. Since the sputum culture was positive for Mycobacterium chelonae, tuberculostatic treatment was replaced with clarithromycin, ethambutol, and linezolid dosed at 1200 mg daily. Three months after the treatment modification, she was readmitted for symptoms of dyspepsia, diarrhoea, and major asthenia. Analytical tests revealed normocytic
